Targeted immunotherapy for renal cancer

Targeted immunotherapy for renal cancer is a new method that has been developed in recent years. What is targeted immunotherapy for renal cancer? Tumor growth depends on the formation of tumor blood vessels and the supply of nutrients. When a tumor grows to a certain size, it needs new blood vessels to provide nutrients. Only by blocking the formation of new tumor blood vessels can the tumor growth be stopped and the tumor tissue be necrotic.

The formation of blood vessels mainly depends on the continuous proliferation of endothelial cells, and the proliferation of endothelial cells depends on the genes of vascular endothelial growth factor (VEGF, PDGF, etc.). Most targeted therapeutic drugs are aimed at angiogenesis, blocking a certain important gene for angiogenesis. After the blockage, angiogenesis is prevented and the tumor will not grow. This kind of targeting of the vascular endothelial growth factor gene, blocking angiogenesis to prevent tumor growth is called targeted therapy.
The effect of targeted therapy is still certain at present, because kidney cancer is not sensitive to radiotherapy and chemotherapy, and the only means is surgical treatment. How to treat the lesions that cannot be removed or metastasized by surgery? In the past, biological treatments were used when they were not sensitive, such as interferon, interleukin II, etc. These drugs are useful in large doses, but they have side effects and many patients cannot tolerate them. Therefore, we continue to research and explore some new methods. In the past two or three years, targeted therapy has appeared, proving that it is effective for kidney cancer, especially for lesions that cannot be removed and metastasized.